Progeneer Information

Progeneer is a biotechnology company developing next-generation immunotherapies and vaccine technologies designed to unlock the full potential of innate immune activation. Our proprietary ProLNG™ platform is built around TLR7/8 agonists engineered to enable controlled activation and targeted delivery to local and regional lymphatic tissues, with the goal of maximizing immune responses while minimizing systemic exposure and reactogenicity. Leveraging ProLNG™, we are advancing programs across therapeutic cancer vaccines, immuno-oncology, and next-generation vaccine adjuvants, while actively pursuing partnerships and co-development opportunities with biotechnology and pharmaceutical companies worldwide. From early discovery and formulation to translational development and clinical strategy, Progeneer is committed to transforming powerful innate immune mechanisms into practical and differentiated therapeutic solutions. Key Areas • TLR7/8 agonist platform • Therapeutic cancer vaccines • Immuno-oncology • Vaccine adjuvants • Drug delivery & lymphatic targeting • Global licensing and co-development